格隆汇1月29日丨中恒集团(600252.SH)公布， 公司预计2025年年度实现归属于母公司所有者的净利润 为-4.5亿元到-2.5亿元。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为-4亿元 到-2亿元。 (二)非经营性损益的影响。1.公司本期将结构化主体纳入合并财务报表范围，因相关资产公允价值变动 形成损失约6000万元；2.公司委托理财产品本期公允价值下跌确认相关损失约1000万元。 (一)主营业务影响。1.公司主要产品销量及单价下降，导致公司营业收入和毛利同比减少；2.控股子公 司业绩未达预期，其商誉减值及其业绩预计减少公司净利润约1.1亿元；3.公司对预期将出现信用风险的 债权进行分析判断，并计提相应的信用减值损失约8000万元；4.公司对闲置设备、不动产等出现减值迹 象的长期资产进行减值测试并确认减值准备约5500万元。 本期业绩预亏的主要原因： ...

Core Viewpoint - Zhongheng Group has announced an annual performance forecast indicating a significant net loss for 2025, with expected net profit attributable to shareholders ranging from -250 million to -450 million yuan, and a net profit excluding non-recurring losses expected to be between -200 million and -400 million yuan [1] Group 1: Main Business Impact - The decline in sales volume and unit price of the company's main products has led to a year-on-year decrease in operating revenue and gross profit [1] - The performance of a controlling subsidiary did not meet expectations, resulting in goodwill impairment and a projected reduction in net profit by approximately 110 million yuan [1] - The company has assessed credit risks on expected non-performing receivables, leading to a provision for credit impairment losses of about 8 million yuan [1] - Impairment tests on idle equipment and long-term assets showing signs of impairment have resulted in a recognition of impairment provisions of approximately 5.5 million yuan [1] Group 2: Non-Operating Loss Impact - The company has included structured entities in its consolidated financial statements, resulting in a loss of approximately 60 million yuan due to changes in the fair value of related assets [1] - The fair value decline of entrusted financial products has led to a recognition of related losses of about 10 million yuan [1]

Core Viewpoint - Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. under Zhongheng Group's "Morning Bell" brand is set to be included in the 2025 China Consumer Brand List, marking a significant milestone in its brand development and recognition as a national quality consumer brand [1][2]. Group 1 - The 2025 China Consumer Brand List is the first national-level consumer brand evaluation led by the Ministry of Industry and Information Technology, aimed at promoting consumption upgrades and cultivating globally recognized brands [1]. - The "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (freeze-dried), which has received multiple awards, including the National Science and Technology Progress Award (Second Class) and the China Patent Excellence Award [1]. - The company emphasizes its development philosophy of "Creating Quality Chinese Medicine to Protect People's Health" and integrates traditional Chinese medicine wisdom with modern pharmaceutical technology [1]. Group 2 - Wuzhou Pharmaceutical is committed to increasing R&D investment through its national-level technology center and collaborative innovation platforms, focusing on modernizing and refining the "Morning Bell" brand products [2]. - The company aims to leverage its inclusion in the China Consumer Brand List to enhance brand development, accelerate innovation-driven growth, and expand its market presence [2].

依托梧州制药"造中华好药护人民健康"的发展理念，"晨钟"品牌以全产业链质控体系坚守品质初心。企 业深耕中医药创新领域，将传统中医药智慧与现代制药技术深度融合，生产车间配备符合国际标准的洁 净生产线，关键工序自动化率达95%以上，通过系统集成实现质量控制全流程数字化管理。凭借稳定可 靠的疗效与安全放心的品质，"晨钟"品牌市场覆盖全国31个省区市，同时入选2025年《中国500最具价 值品牌》榜单，品牌价值评估达82.16亿元人民币，位列榜单第489位。 研发创新是"晨钟"品牌活力的核心动力。梧州制药依托国家级技术中心和产学研协同创新平台，加大研 发投入，推动"晨钟"产品向现代化、精细化、系列化升级，稳固核心产品市场优势，攻克中医药现代化 技术壁垒，为品牌注入持续活力。 本报讯 近日，工信部2025年度中国消费名品名单公示期结束，广西梧州中恒集团股份有限公司旗下广西梧州制 药（集团）股份有限公司（以下简称"梧州制药"）"晨钟"品牌成功入选。此次系工信部首届国家级消费 品牌评选，旨在打造中国品质名品方阵，助力消费升级与全球品牌培育，"晨钟"入选标志着其跻身国家 级优质消费品牌，成为梧州制药品牌建设的重要里程碑。 " ...

Core Viewpoint - The report highlights the growth of industrial enterprises in Guangxi Zhuang Autonomous Region, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1]. Group 1: Industrial Enterprises in Guangxi - As of January-November 2025, the number of industrial enterprises in Guangxi reached 10,535, an increase of 239 enterprises compared to the same period last year, representing a growth rate of 2.32% [1]. - The industrial enterprises accounted for 2% of the national total, reflecting Guangxi's contribution to the overall industrial landscape in China [1]. Group 2: Industry Research and Consulting - Zhiyan Consulting, a leading industry consulting firm in China, has been deeply engaged in industry research for over a decade, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1]. - The firm emphasizes its professional approach, quality service, and keen market insights to empower investment decisions [1].

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

Core Viewpoint - Zhongheng Group (600252) anticipates a negative net profit for the fiscal year 2025, indicating a significant operational loss [1] Group 1: Financial Performance - The company reported a drastic decline in net profit for 2024, with a year-on-year decrease of 547.14% to -377 million yuan, marking the second annual loss since its listing [1][2] - In the first three quarters of 2025, the company achieved total revenue of 1.948 billion yuan, a year-on-year increase of 1.10%, and a net profit of 24.64 million yuan, up 119.61% [2] - Despite the profit growth in early 2025, the company expects a negative net profit for the entire year, indicating substantial losses in the fourth quarter [2] Group 2: Key Financial Metrics - The company's gross margin plummeted from 61.45% in 2023 to 43.21% in 2024, and further down to 31.92% in the first three quarters of 2025 [2] - The net profit margin deteriorated from 0.98% in 2023 to -24.27% in 2024, remaining at -0.48% in the first three quarters of 2025 [2] Group 3: Debt and Financial Position - As of the end of the third quarter of 2025, short-term borrowings increased by 21.4% compared to the end of the previous year, accounting for a 2.43% rise in total assets [3] - Long-term borrowings rose by 47.52%, contributing to a 1.94% increase in total assets [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）财务部门初步测算，预计2025年年 度归属于上市公司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，尽快披露2025 年年度业绩预告。最终财务数据请以公司正式披露的2025年年度报告为准。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站（www.sse.com.cn），有关公司信息均以公司在上述指定媒体披露信息为准。敬请广大投资者理 性投资，注意投资风险。 特此公告。 广西梧州中恒集团股份有限公司 董事会 2026年1月12日 ...

公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，尽快披露2025 年年度业绩预告。最终财务数据请以公司正式披露的2025年年度报告为准。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站（www.sse.com.cn），有关公司信息均以公司在上述指定媒体披露信息为准。敬请广大投资者理 性投资，注意投资风险。 特此公告。 （以下无正文） 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2026-5 广西梧州中恒集团股份有限公司 关于2025年年度业绩预告的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）财务部门初步测算，预计2025年年 度归属于上市公司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 广西梧州中恒集团股份有限公司董事会 2026年1月12日 （此页无正文，仅为《广西梧州中恒集团股份有限公司关 ...

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]